Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06572085 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients

StatusRecruiting
PhasePhase 4
SponsorTang Ziren
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates: Dec 31, 2024 to Dec 31, 2027v3
  2. Notable Primary endpoint revised
    • Eligibility criteria expanded, about 10 words
    v2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
7 trials monitored
See 1 trial at risk
8,786 trials monitored
See 412 trials at risk
Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die. The effectiveness of drugs to improve neurological function in resuscitated brain-injured patients has been a focus of research in the field of resuscitation. Butanephthalein has an ameliorating effect on the damage of central nervous function in patients with acute ischemic stroke, and can promote the improvement of patients' neurological deficits. On this basis, the present study was designed as a multicenter, prospective randomized controlled experiment, with internationally accepted methods for assessing near-term and long-term neurological function, to determine the effectiveness of butalbital in improving neurological function after cardiac arrest, with the aim of searching for new methods and ideas to improve neurological function and prognosis after cardiac arrest.
Trial Details
NCT Number NCT06572085
Lead Sponsor Tang Ziren
Conditions
(from sponsor)
Butylphthalide, Cardiac Arrest, Neuroprotective Drugs
Related terms Heart Arrest
Enrollment 350 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov